{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:45:28Z","timestamp":1780937128458,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clinre.2015.06.011","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T09:37:44Z","timestamp":1437385064000},"page":"S75-S79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S1","title":["New therapies for hepatic fibrosis"],"prefix":"10.1016","volume":"39","author":[{"given":"Yukinori","family":"Koyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2573-525X","authenticated-orcid":false,"given":"David A.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2015.06.011_bib0250","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1517\/13543784.2015.997874","article-title":"Early to phase II drugs currently under investigation for the treatment of liver fibrosis","volume":"24","author":"Hauff","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinre.2015.06.011_bib0255","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1016\/S1074-5521(98)90615-9","article-title":"Caspases: key mediators of apoptosis","volume":"5","author":"Thornberry NA:","year":"1998","journal-title":"Chem Biol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0260","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/jpet.103.060129","article-title":"The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse","volume":"308","author":"Canbay","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinre.2015.06.011_bib0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/hepr.12165","article-title":"Effects of oral intake of hydrogen water on liver fibrogenesis in mice","volume":"44","author":"Koyama","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2015.06.011_bib0270","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2015.06.011_bib0275","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","article-title":"Inhibition of fibrocyte differentiation by serum amyloid P","volume":"171","author":"Pilling","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0280","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1189\/jlb.1MR0114-068R","article-title":"Serum amyloid P: a systemic regulator of the innate immune response","volume":"96","author":"Cox","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0285","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1189\/jlb.0112033","article-title":"FcgammaRI mediates serum amyloid P inhibition of fibrocyte differentiation","volume":"92","author":"Crawford","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0290","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.4049\/jimmunol.179.6.4035","article-title":"Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P","volume":"179","author":"Pilling","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0295","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1042\/bst0260653","article-title":"Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells","volume":"26","author":"Fadok","year":"1998","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.clinre.2015.06.011_bib0300","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1073\/pnas.0832466100","article-title":"Transglutaminase 2-\/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells","volume":"100","author":"Szondy","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2015.06.011_bib0305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000341704","article-title":"TGF-beta signaling in onset and progression of hepatocellular carcinoma","volume":"30","author":"Meindl-Beinker","year":"2012","journal-title":"Dig Dis"},{"key":"10.1016\/j.clinre.2015.06.011_bib0310","doi-asserted-by":"crossref","first-page":"e82190","DOI":"10.1371\/journal.pone.0082190","article-title":"Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-beta1","volume":"8","author":"Fan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2015.06.011_bib0315","doi-asserted-by":"crossref","first-page":"e54499","DOI":"10.1371\/journal.pone.0054499","article-title":"Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats","volume":"8","author":"Ling","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2015.06.011_bib0320","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","article-title":"Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008)","volume":"64","author":"Lacouture","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clinre.2015.06.011_bib0325","doi-asserted-by":"crossref","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2015.06.011_bib0330","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2011.33","article-title":"A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis","volume":"79","author":"Trachtman","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinre.2015.06.011_bib0335","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2967\/jnumed.111.092809","article-title":"PET with the 89Zr-labeled transforming growth factor-beta antibody fresolimumab in tumor models","volume":"52","author":"Oude Munnink","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clinre.2015.06.011_bib0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/sj.bjp.0706172","article-title":"Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis","volume":"145","author":"de Gouville","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1358\/dnp.2006.19.2.977444","article-title":"Inhibition of ALK5 as a new approach to treat liver fibrotic diseases","volume":"19","author":"de Gouville","year":"2006","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.clinre.2015.06.011_bib0350","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of alphavbeta6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0355","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0360","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/TP.0b013e3182884866","article-title":"Role of integrin alphavbeta6 in the pathogenesis of ischemia-related biliary fibrosis after liver transplantation","volume":"95","author":"Chen","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.clinre.2015.06.011_bib0365","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc1143","article-title":"The emerging role of lysophosphatidic acid in cancer","volume":"3","author":"Mills","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinre.2015.06.011_bib0370","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.24485","article-title":"Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts","volume":"54","author":"Mazzocca","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0375","doi-asserted-by":"crossref","DOI":"10.1111\/exd.12752","article-title":"Anti-fibrotic effect of lysophosphatidic acid receptors LPA and LPA antagonist on experimental murine scleroderma induced by bleomycin","author":"Ohashi","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0380","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1476-5381.2010.00828.x","article-title":"A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model","volume":"160","author":"Swaney","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0385","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0390","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0395","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.taap.2013.08.009","article-title":"TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways","volume":"272","author":"Fang","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0400","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.taap.2014.08.006","article-title":"TGF-beta1-elevated TRPM7 channel regulates collagen expression in hepatic stellate cells via TGF-beta1\/Smad pathway","volume":"280","author":"Fang","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0405","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.27348","article-title":"Mouse hepatocyte overexpression of NF-kappaB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis","volume":"60","author":"Shen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0410","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bpg.2011.02.011","article-title":"Anti-fibrogenic strategies and the regression of fibrosis","volume":"25","author":"Kisseleva","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0415","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2015.06.011_bib0420","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10620-010-1507-8","article-title":"The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort","volume":"56","author":"Abu Dayyeh","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2015.06.011_bib0425","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/hep.24281","article-title":"The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2\/gp91(phox) mediate hepatic fibrosis in mice","volume":"53","author":"Paik","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0430","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1089\/ars.2013.5619","article-title":"Role of NADPH oxidases in liver fibrosis","volume":"20","author":"Paik","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.clinre.2015.06.011_bib0435","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.abb.2007.04.016","article-title":"NOX in liver fibrosis","volume":"462","author":"De Minicis","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.clinre.2015.06.011_bib0440","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.23804","article-title":"Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis","volume":"52","author":"De Minicis","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0445","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.3390\/ijms16047057","article-title":"Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation","volume":"16","author":"Patsenker","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2015.06.011_bib0450","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0455","doi-asserted-by":"crossref","first-page":"G850","DOI":"10.1152\/ajpgi.00523.2007","article-title":"Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases","volume":"294","author":"Pacher","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clinre.2015.06.011_bib0460","first-page":"2052","article-title":"Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells","volume":"61","author":"Dai","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0465","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/liv.12263","article-title":"The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives","volume":"33","author":"Baldassarre","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2015.06.011_bib0470","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.20425","article-title":"Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats","volume":"40","author":"Parsons","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.011_bib0475","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1074\/jbc.M111490200","article-title":"Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis","volume":"277","author":"Murphy","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinre.2015.06.011_bib0480","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2015.06.011_bib0485","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40139-013-0018-7","article-title":"Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts","volume":"1","author":"Liu","year":"2013","journal-title":"Curr Pathobiol Rep"},{"key":"10.1016\/j.clinre.2015.06.011_bib0490","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J Clin Invest"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074011500145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074011500145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:13Z","timestamp":1761895393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221074011500145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":49,"alternative-id":["S221074011500145X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2015.06.011","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapies for hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2015.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}